Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Deborah M. Stephens, John C. Byrd

Blood (2021) 138 (13): 1099–1109.

https://doi.org/10.1182/blood.2020006783

Published: 2021

Journal Articles

Core Transcriptional Regulatory Circuitries in AML

Maxim Pimkin, MD PhD, Juliana Xavier Ferrucio, PhD, Neekesh Vijay Dharia, MD PhD, Taku Harada, Andrew Kossenkov, Selma Elsarrag, Jazmin Ewers, Charles Y Lin, PhD, Kimberly Stegmaier, MD, Stuart H. Orkin, MD

Blood (2019) 134 (Supplement_1): 280.

https://doi.org/10.1182/blood-2019-129297

Published: 2019

Journal Articles

MAPK-ERK Pathway Activation: The Achilles' Heel of IL-7R‒Induced Steroid Resistance

Jordy C.G. Van Der Zwet, MD, Jessica G.C.A.M. Buijs-Gladdines, Willem K. Smits, Zhongli Chen, MSc, Jules P.P. Meijerink, PhD

Blood (2019) 134 (Supplement_1): 1292.

https://doi.org/10.1182/blood-2019-124721

Published: 2019

Journal Articles

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

B. Hilda Ye, PhD, Elaine Chung, PhD, Kith Pradhan, PhD, Ana Acuna-Villaorduna, MD, Yanhua Wang, MD PhD, Aditi Shastri, MD, Advaitha Madireddy, PhD, Amit Verma, MBBS, R.Alejandro Sica, MD, Murali Janakiram, MD MS

Blood (2019) 134 (Supplement_1): 3779.

https://doi.org/10.1182/blood-2019-131364

Published: 2019

Journal Articles

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, Anne Lehman, Grace Jeschke, PhD, John D. Crispino, PhD MBA, Thierry Besson, PhD, Sarah K. Tasian, MD, Martin Carroll, MD

Blood (2019) 134 (Supplement_1): 2742.

https://doi.org/10.1182/blood-2019-123475

Published: 2019

Journal Articles

Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors

Daniel Mertens, PhD, Christine Wolf, PhD, Carsten Maus, PhD, Michael Persicke, Katharina Filarsky, PhD, Hartmut Döhner, Peter Lichter, PhD, Thomas Höfer, PhD, Stephan Stilgenbauer, MD

Blood (2019) 134 (Supplement_1): 4275.

https://doi.org/10.1182/blood-2019-127837

Published: 2019

Journal Articles

MYC Overexpressing Multiple Myeloma Are Dependent on GLS1

Katarina K Jovanovic, PhD, Léa Fléchon, MSc, Mairead Reidy, PhD, Jihye Park, BS, DVM, Xavier Leleu, MD PhD, Irene M. Ghobrial, MD, Thierry Facon, MD, Bruno Quesnel, Salomon Manier, MD PhD

Blood (2019) 134 (Supplement_1): 853.

https://doi.org/10.1182/blood-2019-128484

Published: 2019

Journal Articles

Myc and the Warburg Effect

Stefano Casola, MD PhD, Gabriele Varano, Laura Perucho, Marianna Ossorio, Federica Zanardi, Martina Sormani, Valentina Petrocelli, Christin Zasada, Stefan Kempa, Klaus Rajewsky, Maurilio Ponzoni, MD, Fabio Facchetti

Blood (2018) 132 (Supplement 1): SCI-12.

https://doi.org/10.1182/blood-2018-99-109471

Published: 2018

Journal Articles

AML Cells Express Exclusively the Long Isoform of LEF1 and Are Highly Vulnerable to Blockage of LEF1-β-Catenin Binding

Kristin Feder, MSc, Katrin Elisabeth Edmaier-Schröger, PhD, Nicole Kirsten, PhD, Linda Geisdorf, Naidu Vegi, PhD, Klaus H. Metzeler, MD, Michaela Feuring-Buske, MD, Christian Buske, MD

Blood (2018) 132 (Supplement 1): 3913.

https://doi.org/10.1182/blood-2018-99-116552

Published: 2018

Journal Articles

Arginine Depletion in Combination with Canavanine Supplementation Induces Massive Cell Death in Myeloma Cells By Interfering with Their Protein Metabolism and Bypassing Potential Rescue Mechanisms

Johannes Windschmitt, Björn Jacobi, MD, Yagmur Bülbül, Lilli Sester, Janine Tappe, Christof Hiebel, PhD, Christian Behl, PhD, Matthias Theobald, Markus Munder, MD

Blood (2018) 132 (Supplement 1): 3205.

https://doi.org/10.1182/blood-2018-99-113396

Published: 2018

Journal Articles

Founding Precision Therapy in 1q-Amplified Multiple Myeloma

Romanos Sklavenitis-Pistofidis, MD, Mairead Reidy, PhD, Daisy Huynh, MS, Karma Ziad Salem, MD, Jihye Park, PhD, Siobhan Glavey, MD PhD, Xavier Leleu, MD PhD, David Root, PhD, Irene M. Ghobrial, MD, Salomon Manier, MD PhD

Blood (2018) 132 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2018-99-112673

Published: 2018

Journal Articles

Brief Ex Vivo Incubation with Fas Ligand Selectively Depletes Alloreactive T Cells and Antigen Presenting Cells from Stem Cell Grafts

Hilit Levy-Barazany, PhD, Liat Pinkas, PhD, Galina Rodionov, Nitzan Marelly, Michal Tzadok, Hila Wildbaum, Tamar Katz, PhD, Ronit Bakimer, PhD, Shai Yarkoni, MD PhD, Amnon Peled, Jerry Stein, MD, Tsila Zuckerman, MD

Blood (2018) 132 (Supplement 1): 2033.

https://doi.org/10.1182/blood-2018-99-117920

Published: 2018

Journal Articles

Dual PI3K blockade: PTCL’s Achilles heel?

Jonathan E. Brammer

Blood (2018) 131 (8): 839–840.

https://doi.org/10.1182/blood-2017-12-820258

Published: 2018

Journal Articles

Integrative Analysis of the Genomic Landscape Underlying Multiple Myeloma at Diagnosis: An Mmrf Commpass Analysis

Austin Christofferson, BS, Sara Nasser, Jessica Aldrich, Daniel Penaherrera, Christophe Legendre, Brooks Benard, BS, Sheri Skerget, PhD, The MMRF CoMMpass Network, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Jonathan Keats, PhD

Blood (2017) 130 (Supplement 1): 326.

https://doi.org/10.1182/blood.V130.Suppl_1.326.326

Published: 2017

Journal Articles

Normal Plasma Cell Biology: Natural Achilles Heels as Targets in Myeloma

Katia Georgopoulos, PhD

Blood (2017) 130 (Supplement 1): SCI-7.

https://doi.org/10.1182/blood.V130.Suppl_1.SCI-7.SCI-7

Published: 2017

Journal Articles

The Transcriptome Heterogeneity of MLL-Fusion ALL Is Driven By Fusion Partners Via Distinct Chromatin Binding

Shan Lin, Anetta Ptasinska, PhD, Salam Adli Assi, Jon Kerry, Ruhikanta A. Meetei, PhD, Roger T. Luo, PhD, Michael J. Thirman, MD, Thomas Milne, PhD, Constanze Bonifer, PhD, James C. Mulloy, PhD

Blood (2016) 128 (22): 576.

https://doi.org/10.1182/blood.V128.22.576.576

Published: 2016

Journal Articles

Characterization of Lineage Vs. Context-Dependent Essential Genes in Multiple Myeloma Using Crispr/Cas9 Genome Editing

Geoffrey M. Matthews, PhD, Ricardo De Matos Simoes, PhD, Yiguo Hu, MD PhD, Michal Sheffer, PhD, Eugen Dhimolea, PhD, Paul J. Hengeveld, B.Sc., Megan A. Bariteau, BSc, Brian Glassner, PhD, Quinlan Sievers, BA, Benjamin L. Ebert, MD PhD, Sara Gandolfi, MD, Pallavi Awate, MSc, Huihui Tang, PhD, Franciska Vazquez, PhD, Aedin Culhane, PhD, Constantine S Mitsiades, MD PhD

Blood (2016) 128 (22): 119.

https://doi.org/10.1182/blood.V128.22.119.119

Published: 2016

Journal Articles

Restoring the Lost B-Cell Phenotype Renders Classical Hodgkin's Lymphoma Susceptible to B-Cell-Targeting Therapies

Nina Rosa Neuendorff, MD, Jing Du, PhD, Yong Yu, PhD, Jens Peter von Kries, PhD, Stephan Mathas, MD, Bernd Dörken, Prof., Soyoung Lee, PhD, Clemens A. Schmitt, MD Prof

Blood (2016) 128 (22): 1094.

https://doi.org/10.1182/blood.V128.22.1094.1094

Published: 2016

Journal Articles

Management of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) - Data from the Spanish PNH Registry

Silvia De La Iglesia Iñigo, MD PhD, Cristina Notario McDonell, MD, Anna Gaya Valls, María Teresa Cedena Romero, MD PhD, María Isabel Gómez Roncero, MD, Beatriz Arrizabalaga Amunchastegui, MD PhD, Carmen Monteserin Monteserin, MD, Esperanza Lavilla Rubira, MD PhD, Ana María Villegas Martínez, Prof.

Blood (2016) 128 (22): 4811.

https://doi.org/10.1182/blood.V128.22.4811.4811

Published: 2016

Journal Articles

ER-Stress-Induced Suppression of HLA-E on Bortezomib-Evading Malignant Plasma Cells Dramatically Enhances Their Susceptibility to NK Cell Killing: Identification of an Achilles Heel in Myeloma Cells That Can be Utilized to Prevent Disease Relapse Following Bortezomib Treatment

Mattias Carlsten, MD, PhD, Ali Namazi, MD, Robert N. Reger, B.S., Maria Berg, Richard W. Childs, MD

Blood (2015) 126 (23): 4296.

https://doi.org/10.1182/blood.V126.23.4296.4296

Published: 2015

NARROW

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Core Transcriptional Regulatory Circuitries in AML

MAPK-ERK Pathway Activation: The Achilles' Heel of IL-7R‒Induced Steroid Resistance

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors

MYC Overexpressing Multiple Myeloma Are Dependent on GLS1

Myc and the Warburg Effect

AML Cells Express Exclusively the Long Isoform of LEF1 and Are Highly Vulnerable to Blockage of LEF1-β-Catenin Binding

Arginine Depletion in Combination with Canavanine Supplementation Induces Massive Cell Death in Myeloma Cells By Interfering with Their Protein Metabolism and Bypassing Potential Rescue Mechanisms

Founding Precision Therapy in 1q-Amplified Multiple Myeloma

Brief Ex Vivo Incubation with Fas Ligand Selectively Depletes Alloreactive T Cells and Antigen Presenting Cells from Stem Cell Grafts

Dual PI3K blockade: PTCL’s Achilles heel?

Integrative Analysis of the Genomic Landscape Underlying Multiple Myeloma at Diagnosis: An Mmrf Commpass Analysis

Normal Plasma Cell Biology: Natural Achilles Heels as Targets in Myeloma

The Transcriptome Heterogeneity of MLL-Fusion ALL Is Driven By Fusion Partners Via Distinct Chromatin Binding

Characterization of Lineage Vs. Context-Dependent Essential Genes in Multiple Myeloma Using Crispr/Cas9 Genome Editing

Restoring the Lost B-Cell Phenotype Renders Classical Hodgkin's Lymphoma Susceptible to B-Cell-Targeting Therapies

Management of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) - Data from the Spanish PNH Registry

ER-Stress-Induced Suppression of HLA-E on Bortezomib-Evading Malignant Plasma Cells Dramatically Enhances Their Susceptibility to NK Cell Killing: Identification of an Achilles Heel in Myeloma Cells That Can be Utilized to Prevent Disease Relapse Following Bortezomib Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only